Related Experiment Video
Updated: Sep 5, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Thrombocytopenia and increased risk of adverse outcome in COVID-19 patients
Yang Yuan1, Gang Wang1, Xi Chen2
1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Insights
Thrombocytopenia, a low platelet count, is linked to worse outcomes in COVID-19 patients. Monitoring platelet levels can help assess disease severity and patient prognosis during hospitalization.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Thrombocytopenia (low platelet count) is a common finding in patients with coronavirus disease 2019 (COVID-19).
- The precise role of thrombocytopenia in COVID-19 pathogenesis and its association with the systemic host response remain unclear.
- This study investigates the link between thrombocytopenia and clinical, hematological, biochemical, and outcome markers in COVID-19 patients.
Purpose of the Study:
- To systematically evaluate the relationship between thrombocytopenia in COVID-19 patients and various disease markers.
- To assess the association between abnormal platelet levels and adverse clinical outcomes in COVID-19.
Main Methods:
- A multi-center retrospective cohort study was conducted.
- COVID-19 patients with thrombocytopenia were compared to a matched sub-cohort without thrombocytopenia.
- Data collected included clinical manifestations, hematological disorders, biochemical parameters, inflammatory markers, and clinical outcomes.
Main Results:
- Thrombocytopenia was identified in 127 of 2,209 COVID-19 patients on admission.
- Patients with thrombocytopenia exhibited significantly higher rates of respiratory failure, ICU admission, and disseminated intravascular coagulation.
- Thrombocytopenia was associated with elevated inflammatory markers and a 3.08-fold increased risk of all-cause mortality.
Conclusions:
- Thrombocytopenia is a significant indicator of adverse outcomes in COVID-19 patients.
- Platelet count and indices should be routinely monitored alongside other markers for comprehensive COVID-19 patient assessment.
- Early and late thrombocytopenia are associated with poor prognosis, with late-onset linked to longer mortality duration.
Background:
Thrombocytopenia was common in the coronavirus disease 2019 (COVID-19) patients during the infection, while the role of thrombocytopenia in COVID-19 pathogenesis and its relationship with systemic host response remained obscure. The study aimed to systematically evaluate the relationship between thrombocytopenia in COVID-19 patients and clinical, haematological and biochemical markers of the disease as well as adverse outcomes.
Methods:
To assess the relationship between abnormal platelet levels and disease progression, a multi-center retrospective cohort study was conducted. COVID-19 patients with thrombocytopenia and a sub-cohort of matched patients without thrombocytopenia were compared for their clinical manifestations, haematological disorders, biochemical parameters, inflammatory markers and clinical outcome.
Results:
Thrombocytopenia was present in 127 of 2,209 analyzed patients on admission. Compared with the control group, thrombocytopenia patients developed significantly higher frequency of respiratory failure (41.9% vs. 22.6%, P = 0.020), intensive care unit entrance (25.6% vs. 11.5%, P = 0.012), disseminated intravascular coagulation (45.2% vs. 10.6%, P < 0.001), more altered platelet morphology indexes and coagulation perturbation, higher levels of inflammatory markers. In addition, a significantly increased all-cause mortality (hazard ratio 3.08, 95% confidence interval 2.26-4.18, P < 0.001) was also observed in the patients with thrombocytopenia. Late development of thrombocytopenia beyond 14 days post-symptom was observed in 61 patients, from whom a comparable mortality rate yet longer duration to death was observed compared to those with early thrombocytopenia.
Conclusions:
Our finding from this study adds to previous evidence that thrombocytopenia is associated with adverse outcome of the disease and recommend that platelet count and indices be included alongside other haematological, biochemical and inflammatory markers in COVID-19 patients' assessment during the hospital stay.
Related Concept Videos
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:30Venous Thrombosis IV: Nursing Management
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...